How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy.

Fundytus, A; Booth, C M; Tannock, I F

Fundytus, A; Booth, C M; Tannock, I F.

Afiliação

Fundytus A; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada; Department of Oncology, Queen's University, Kingston, Canada.
Booth CM; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada; Department of Oncology, Queen's University, Kingston, Canada; Department of Public Health Sciences, Queen's University, Kingston, Canada.
Tannock IF; Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada. Electronic address: ian.tannock@uhn.ca.

Ann Oncol ; 32(7): 833-836, 2021 07.

Article em En | MEDLINE | ID: mdl-33839260

Assuntos

Antígeno B7-H1; Neoplasias; Humanos; Imunoterapia; Neoplasias/terapia; Receptor de Morte Celular Programada 1

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Neoplasias Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google